A major step forward for access to mental health treatment in the province.

WINNIPEG, MB, February 18, 2026 — In a landmark development for mental health care in the Prairies, the Enhanced Therapy Institute (ETI) has secured Manitoba’s first Special Access Program (SAP) approval for MDMA-assisted therapy.
This breakthrough allows a Manitoba patient to receive a clinical protocol previously restricted to research trials, marking a significant step forward for people living with treatment-resistant mental health conditions in the province and expanding access to new treatments.
MDMA-assisted therapy has demonstrated significant results in clinical trials for the treatment of PTSD, particularly for patients who have not responded to conventional therapies. Delivered within a structured medical and psychotherapeutic framework, the treatment combines preparatory sessions, supervised medicine sessions, and integration therapy.
This successful application was developed in partnership with TheraPsil, a national non-profit advancing legal access to psychedelic-assisted treatment and clinician training in Canada.
John Gilchrist, Director of Communications at TheraPsil, said,
“This is what the future of mental health care looks like: effective therapies delivered safely in real clinical practice. Canadians deserve regulated access to MDMA-assisted therapy, and this milestone shows it can be delivered today by experienced care teams. We’re proud to work alongside ETI in helping make this treatment a real and scalable option for patients.”
ETI’s leadership team — psychologist Dr. Darek Dawda, host of the MDMA Therapy Podcast, and psychiatrist Dr. Artur Winogrodzki — has spent years collaborating with provincial regulators to establish a framework for the safe, ethical, and professional delivery of psychedelic-assisted treatments. Their multidisciplinary approach ensures that the medical screening and intensive psychotherapy required for this protocol meet the highest clinical standards.
“This approval is a watershed moment for Manitoba,” said Dr. Dawda. “Our hope is to move beyond standard suppression or management of symptoms toward a model that helps people work on the actual resolution of trauma symptoms.”
ETI is in the final stages of formal accreditation with provincial medical authorities and will initially focus on delivering MDMA-assisted therapy for patients living with chronic Post-Traumatic Stress Disorder (PTSD). The team is also exploring the future potential of this therapy to support profound improvements in interpersonal relationships and emotional wellness.
Media contacts
John Gilchrist – Director of Communications, TheraPsil
john@therapsil.ca | 647−505−3964
Darek Dawda – Founder & Clinical Director, Enhanced Therapy Institute
info@enhancedtherapy.ca | 204−226−5678
About Enhanced Therapy Institute (ETI)
Located in Winnipeg, ETI is a multidisciplinary clinic dedicated to providing cutting-edge, evidence-based psychological and psychiatric care. The institute is at the forefront of the psychedelic therapy movement in Canada, prioritizing ethics, patient safety, and lasting therapeutic results. https://enhancedtherapy.ca
About TheraPsil
TheraPsil is a Canadian nonprofit working to legalize and expand access to psychedelic-assisted therapies. Through advocacy, clinical training, and regulatory engagement, the organization has helped open the door for hundreds of Canadians to receive care. https://therapsil.ca.
Download Press Release: First MDMA-Assisted Therapy for PTSD Approved in Manitoba